AU2017358703A1 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases - Google Patents
Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases Download PDFInfo
- Publication number
- AU2017358703A1 AU2017358703A1 AU2017358703A AU2017358703A AU2017358703A1 AU 2017358703 A1 AU2017358703 A1 AU 2017358703A1 AU 2017358703 A AU2017358703 A AU 2017358703A AU 2017358703 A AU2017358703 A AU 2017358703A AU 2017358703 A1 AU2017358703 A1 AU 2017358703A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201618959 | 2016-11-10 | ||
| GB201618962 | 2016-11-10 | ||
| GB201618963 | 2016-11-10 | ||
| GB1618959.9 | 2016-11-10 | ||
| GB1618962.3 | 2016-11-10 | ||
| GB1618963.1 | 2016-11-10 | ||
| GB1618961.5 | 2016-11-10 | ||
| GB1618960.7 | 2016-11-10 | ||
| GB1618964.9 | 2016-11-10 | ||
| GB201618961 | 2016-11-10 | ||
| GB201618964 | 2016-11-10 | ||
| GB201618960 | 2016-11-10 | ||
| PCT/EP2017/078701 WO2018087202A1 (en) | 2016-11-10 | 2017-11-09 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017358703A1 true AU2017358703A1 (en) | 2019-05-09 |
Family
ID=60388032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017358703A Abandoned AU2017358703A1 (en) | 2016-11-10 | 2017-11-09 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190314382A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3538103A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019534304A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017358703A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043396A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019117562A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201821080A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018087202A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019132654A1 (en) * | 2017-12-27 | 2019-07-04 | Erasmus University Medical Center Rotterdam | Methods of treating sarcoidosis |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| WO2020009566A1 (en) * | 2018-07-04 | 2020-01-09 | Erasmus University Medical Center Rotterdam | Methods of treating sarcoidosis |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
| US11602536B2 (en) | 2019-06-10 | 2023-03-14 | Incyte Corporation | Topical treatment of vitiligo by a JAK inhibitor |
| JP7518900B2 (ja) * | 2019-10-16 | 2024-07-18 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| CN115282168B (zh) * | 2022-08-30 | 2024-05-31 | 马应龙大健康有限公司 | 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用 |
| CN119157881A (zh) * | 2024-09-25 | 2024-12-20 | Jje有限公司 | Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070111956A1 (en) | 2003-07-03 | 2007-05-17 | Japan Science And Technology Agency | Remedy for sarcoidosis and method of treating the same |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| DK2830662T3 (da) * | 2012-03-29 | 2019-01-02 | Univ Columbia | Fremgangsmåder til behandlng af hårtabsforstyrrelser |
| MX368511B (es) | 2012-06-22 | 2019-10-07 | Galapagos Nv | Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma. |
| EP3060234A1 (en) * | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| SMT202300328T1 (it) | 2015-04-13 | 2023-11-13 | Galapagos Nv | Metodi per il trattamento di disturbi cardiovascolari |
| KR20170134750A (ko) | 2015-04-13 | 2017-12-06 | 갈라파고스 엔.브이. | 염증 질환의 치료 방법 |
| AU2016259023A1 (en) * | 2015-05-07 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for promoting hair growth |
-
2017
- 2017-11-09 JP JP2019524273A patent/JP2019534304A/ja not_active Withdrawn
- 2017-11-09 AU AU2017358703A patent/AU2017358703A1/en not_active Abandoned
- 2017-11-09 EP EP17800795.1A patent/EP3538103A1/en not_active Withdrawn
- 2017-11-09 RU RU2019117562A patent/RU2019117562A/ru not_active Application Discontinuation
- 2017-11-09 WO PCT/EP2017/078701 patent/WO2018087202A1/en not_active Ceased
- 2017-11-09 CA CA3043396A patent/CA3043396A1/en not_active Abandoned
- 2017-11-09 US US16/348,799 patent/US20190314382A1/en not_active Abandoned
- 2017-11-10 TW TW106139074A patent/TW201821080A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3538103A1 (en) | 2019-09-18 |
| TW201821080A (zh) | 2018-06-16 |
| JP2019534304A (ja) | 2019-11-28 |
| WO2018087202A1 (en) | 2018-05-17 |
| US20190314382A1 (en) | 2019-10-17 |
| RU2019117562A (ru) | 2020-12-10 |
| RU2019117562A3 (cg-RX-API-DMAC7.html) | 2021-02-09 |
| CA3043396A1 (en) | 2018-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018087202A1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases | |
| US12370195B2 (en) | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | |
| TWI887465B (zh) | 用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法 | |
| TWI535701B (zh) | 使用選擇性bcl-2抑制劑之治療方法 | |
| US20220281882A1 (en) | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | |
| US11512092B2 (en) | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | |
| US20220251101A1 (en) | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | |
| JP7751362B2 (ja) | 乾癬性関節炎の治療方法 | |
| JP2023542878A (ja) | 多発性硬化症を治療するためのlou064 | |
| US11993606B2 (en) | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | |
| TWI836022B (zh) | 治療纖維化之方法 | |
| US20140127295A1 (en) | Compositions, process of preparation of said compositions and method of treating inflammatory diseases | |
| US12570664B2 (en) | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |